6 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp05484 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | MCF-7 | Breast cancer | LC50 : 8 at 100 µM |
| dbacp05485 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | LNCaP | Prostate cancer | LC50 : 6 at 100 µM |
| dbacp05486 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | OVRCAR-3 | Ovarian cancer | LC50 : 13 at 100 µM |
| dbacp05487 | Pexiganan acetate | GIGKFLKKAKKFGKAFVKILKK | Engineered | Disruption of membrane permeability | MTT/MTS assay | U-937 | Lymphoma cancer | 75% Cytotoxicity at 0.5 µg/ml |
| dbacp05488 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-941 | Lymphoma cancer | IC50 : 20-30 µg/ml |
| dbacp05489 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Helical peptide with a predominance of one or more amino acids tryptophane-rich | Disruption of membrane permeability | MTT/MTS assay | U-937 | Lymphoma cancer | 75% Cytotoxicity at 0.5 µg/ml |